Processa Pharmaceuticals, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $320 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $320.00, a 77.76% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $8.96K, a 346.46% increase year-over-year.
- Processa Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-03-31 was $1.44K, a 85.50% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-09-30 was $3.66K.
- Processa Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $10.40K, a 34.57% decline from fiscal 2024.
- Processa Pharmaceuticals, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $15.90K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-03-31 | $320.00 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $10.40K 10-K · filed 2026-03-18 | |||
| 2025-06-30 | $8.96K 10-Q · filed 2026-08-14 | $10.40K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $1.44K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $15.90K 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $3.66K 10-Q · filed 2025-11-06 | $5.67K derived: sum of 2 quarters · filed 2025-11-06 | $15.59K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $2.01K 10-Q · filed 2025-11-06 | $11.93K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $9.92K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |